X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.pharmaceutical-technology.com/news/nhs-pfizer-voxelotor-sickle-cell-disease/
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-voxelotor-tablets-12918.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-voxelotor-tablets-for-oral-suspension-71916.pdf
https://www.ema.europa.eu/en/documents/overview/oxbryta-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/oxbryta-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/novartiss-adakveo-couldnt-beat-placebo-ema-review-its-current-authorization
https://www.globenewswire.com/news-release/2022/07/26/2485565/37049/en/MHRA-Grants-Marketing-Authorization-for-GBT-s-Oxbryta-voxelotor-for-Use-in-Great-Britain-for-the-Treatment-of-Hemolytic-Anemia-in-Patients-with-Sickle-Cell-Disease-Age-12-Years-and.html
https://www.pharmatimes.com/news/mhra_grants_marketing_authorisation_for_global_blood_therapeuticss_oxbryta_1452667
https://www.globenewswire.com/news-release/2022/07/14/2479652/37049/en/GBT-Initiates-Expanded-Access-Program-for-Voxelotor-in-Patients-With-Sickle-Cell-Disease-in-Brazil.html
https://www.globenewswire.com/news-release/2022/05/04/2436105/37049/en/GBT-Reports-First-Quarter-2022-Financial-Results.html
https://www.prnewswire.com/news-releases/european-medicines-agency-approves-oxbryta-voxelotor-first-treatment-approved-in-the-eu-to-target-the-cause-of-sickle-cell-disease-301490103.html
https://www.globenewswire.com/news-release/2022/01/27/2374009/37049/en/Positive-Early-Access-to-Medicines-Scheme-EAMS-Scientific-Opinion-Awarded-to-GBT-s-Voxelotor-for-the-Treatment-of-Haemolytic-Anaemia-Due-to-Sickle-Cell-Disease.html
https://www.globenewswire.com/news-release/2021/12/17/2354674/37049/en/U-S-FDA-Approves-Supplemental-New-Drug-Application-for-Expanded-Indication-of-Oxbryta-voxelotor-for-Children-as-Young-as-4-Years-of-Age-with-Sickle-Cell-Disease.html
https://www.globenewswire.com/news-release/2021/12/17/2354591/37049/en/GBT-s-Oxbryta-voxelotor-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Hemolytic-Anemia-in-Patients-with-Sickle-Cell-Disease-Aged-12-Years-and-Older.html
https://ir.gbt.com/news-releases/news-release-details/us-fda-approves-supplemental-new-drug-application-expanded
https://www.globenewswire.com/news-release/2021/11/01/2324373/37049/en/GBT-Wins-Prestigious-Prix-Galien-USA-Award-for-Oxbryta-voxelotor.html
https://www.globenewswire.com/news-release/2021/09/07/2292458/37049/en/U-S-FDA-Accepts-for-Priority-Review-Supplemental-New-Drug-Application-for-Oxbryta-voxelotor-for-the-Treatment-of-Sickle-Cell-Disease-in-Children-Ages-4-to-11.html
https://www.globenewswire.com/news-release/2021/06/14/2246402/37049/en/GBT-s-Voxelotor-is-First-Sickle-Cell-Disease-Treatment-to-Receive-Promising-Innovative-Medicine-PIM-Designation-in-the-UK.html
https://www.globenewswire.com/news-release/2021/04/08/2206372/37049/en/Complete-72-Week-Results-from-Phase-3-HOPE-Study-of-Oxbryta-voxelotor-Tablets-Published-in-The-Lancet-Haematology-Show-Significantly-Improved-Hemoglobin-Hemolysis-and-Overall-Healt.html
https://endpts.com/with-all-the-buzz-in-gene-therapy-sanofi-offloads-two-small-molecule-sickle-cell-programs-from-11-6b-buyout-to-global-blood-therapeutics/
https://www.globenewswire.com/fr/news-release/2021/02/04/2169902/0/en/GBT-Initiates-Expanded-Access-Protocol-for-Oxbryta-voxelotor-in-Pediatric-Patients-with-Sickle-Cell-Disease-in-the-United-States.html
http://www.pharmatimes.com/news/ema_begins_review_of_gbts_sickle_cell_treatment_oxbryta_1362312
http://www.pharmatimes.com/news/ema_begins_review_of_gbts_sickle_cell_treatment_oxbryta_1362312
https://www.globenewswire.com/news-release/2020/12/06/2140175/0/en/GBT-Presents-New-Data-on-the-Long-Term-and-Real-World-Use-of-Oxbryta-voxelotor-Tablets-in-Patients-with-Sickle-Cell-Disease-at-62nd-ASH-Annual-Meeting-and-Exposition.html
https://www.globenewswire.com/news-release/2020/10/12/2106797/0/en/GBT-Receives-Rare-Impact-Award-for-Innovation-from-the-National-Organization-of-Rare-Disorders-NORD-for-Development-of-Oxbryta-voxelotor-Tablets.html
https://www.globenewswire.com/news-release/2020/09/08/2090432/0/en/GBT-and-Biopharma-MEA-Enter-Agreement-to-Distribute-Oxbryta-voxelotor-in-Six-Middle-Eastern-Countries.html#:~:text=(GBT)%20(NASDAQ%3A%20GBT,the%20Gulf%20Cooperation%20Council%20(GCC)
https://www.globenewswire.com/news-release/2020/06/24/2052733/0/en/GBT-Announces-Plans-to-Seek-Regulatory-Approval-for-Oxbryta-voxelotor-to-Treat-Sickle-Cell-Patients-in-Europe.html
https://www.globenewswire.com/news-release/2020/06/08/2045202/0/en/GBT-Announces-Plans-to-Seek-Expanded-Labeling-for-Oxbryta-voxelotor-to-Treat-Children-Ages-4-to-11-Years-with-Sickle-Cell-Disease.html
https://www.fiercepharma.com/marketing/despite-strong-start-covid-19-brought-clear-slowdown-patient-starts-for-oxbryta-gbt-ceo
https://www.fiercepharma.com/marketing/gbt-looks-to-take-a-page-from-hiv-playbook-as-it-embarks-oxbryta-launch
https://endpts.com/at-jpm20-two-ceos-two-radically-different-therapies-and-a-fight-to-chase-down-sickle-cell/
https://www.fiercepharma.com/pharma/global-blood-therapeutics-scores-fda-nod-for-oxbryta-and-execs-expect-a-paradigm-shift
https://www.biospace.com/article/global-blood-therapeutics-prices-a-200-0-million-common-stock-public-offering/?s=75
https://www.fiercebiotech.com/biotech/gbt-sickle-cell-trial-hits-endpoint-ahead-nda-filing
https://seekingalpha.com/article/4226750-global-blood-therapeutics-gets-quick-advance-surprise-fda
https://endpts.com/gbt-convinces-fda-to-review-sickle-cell-drug-under-accelerated-pathway/
Market Place
Share 
